Johanna Lahdenranta, Ph.D.

Johanna Lahdenranta is the Senior Director of In Vivo Pharmacology at Bicycle Therapeutics. Bicycle Therapeutics is developing a unique class of chemically synthesized medicines based on its proprietary bicyclic peptide (Bicycle®) product platform to address therapeutic needs unreachable with existing treatment modalities. Johanna’s team supports the pre-clinical in vivo pharmacology investigations of Bicycle’s oncology -pipeline including Bicycle Toxin Conjugates®, Bicycle® radio-conjugates and Bicycle® immune cell agonists. Johanna has 15 years of Biotech experience in the field of in vivo pharmacology with drug modalities ranging from small molecules to targeted nanoliposomes. Johanna has trained in cancer biology and tumor vascular physiology and did her graduate work at MD Anderson Cancer Center and received her PhD from University of Helsinki. She did her post-doctoral training at the Massachusetts General Hospital. Before joining Bicycle Therapeutics, Johanna was at FORMA Therapeutics and prior to that at Merrimack Pharmaceuticals.